Qizhu Xuanshen Micropowder Veterinary Grade API is designated by the manufacturer as a micronized botanical-derived active pharmaceutical ingredient for direct incorporation into tablet matrices, capsule fill formulations, injectable compounding, oral powders, granules, feed premixes, and solutions. The product is identified by trade nomenclature rather than by a public pharmacopoeial monograph; the term “Xuanshen” generally corresponds to Scrophulariae Radix in traditional Chinese materia medica, but the exact botanical origin, marker compound profile, and extraction history should be confirmed from the manufacturer’s technical file and batch certificate. The product is supplied as a single veterinary grade; no alternative particle-size models or solubility-enhanced variants are identified in public trade literature.

Material characteristics commonly associated with such micropowder grades include a controlled particle size distribution with D90 below 150 µm, moisture content not exceeding 5.0%, and a heavy metals limit of ≤ 20 ppm when tested by pharmacopoeial general methods. These values are not specific release data for Qizhu Xuanshen; published data for this specific configuration is limited, and the manufacturer’s certificate of analysis remains the normative specification.

Regulatory acceptance for food-producing species requires attention to withdrawal periods and maximum residue limits. No public residue depletion data for Qizhu Xuanshen Micropowder is identified; until such data are established, a default withdrawal period cannot be assigned under 21 CFR 530 or equivalent veterinary medicinal product legislation. The manufacturer should provide marker compound depletion data for the intended species.

Which Pharmacopoeial Release Parameters Apply to This Micropowder Across Tablet, Capsule, and Solution Routes?

Because the product is intended for solid, semi-solid, and liquid veterinary dosage forms, the release specification must simultaneously address content uniformity risk in dry blends, microbial quality in non-sterile oral powders, and endotoxin burden in injectable preparations. For solid dosage forms, particle size distribution, loss on drying, and flow properties are critical. For injections, bacterial endotoxins, sterility, and insoluble particulate matter become release-limiting. The matrix below lists compendial methods commonly selected for veterinary botanical powder APIs; the stated acceptance criteria are typical for botanical micropowders rather than product-specific limits for Qizhu Xuanshen.

Where the API is used for sterile injectable solutions, the endotoxin acceptance criterion is not automatically met by the powder. A validated depyrogenation step such as autoclaving or dry heat, followed by aseptic filtration through a 0.22 µm membrane, is required unless terminal sterilisation is selected. Residual solvent and elemental impurity testing should follow USP <467>, USP <232>, USP <233>, or Ph. Eur. 2.4.24 as applicable. The assay specification for a botanical micropowder should define a suitable marker compound or total active constituent. For Scrophulariae Radix-derived materials, iridoid glycosides such as harpagoside or aucubin are sometimes used as markers, but the exact marker set for Qizhu Xuanshen is not publicly defined. Identification by high-performance thin-layer chromatography should produce a fingerprint consistent with the supplied botanical reference; the absence of a public monograph makes the manufacturer’s reference standard the critical control.

Particle Size Control and Processability in Direct Compression, Granulation, and Capsule Filling

The micropowder designation indicates that particle size reduction has been applied to improve homogeneity and dissolution behaviour compared with crude botanical powders. For direct compression tablet premixes, a D90 below 150 µm reduces segregation risk when the excipient particle size distribution remains within a factor of approximately 1:6 of the API. For dosator-type capsule filling, low bulk density and high cohesion can produce variable fill weights; pre-compaction or addition of 0.5–1.0% fumed silica is a standard intervention, although compatibility with the botanical constituents should be confirmed by content uniformity testing. High-shear granulation with water or ethanol/water mixtures typically requires a moisture endpoint of 2–4% after drying; exceeding 5.0% loss on drying can accelerate microbial growth and reduce granule flow.

On production-scale rotary tablet presses, ejection force for a botanical micropowder-containing formulation may exceed 1.5 kN if lubricant distribution is inadequate. Magnesium stearate at 1.0% blended for 3–5 min is commonly used, but over-lubrication can extend disintegration time. Tablet hardness is generally monitored in the range of 50–120 N, with friability measured according to USP <1216> or Ph. Eur. 2.9.7 at ≤ 1.0%. Content uniformity should be evaluated using USP <905> or Ph. Eur. 2.9.40. Published data for this specific configuration is limited; therefore, these process windows should be verified in development batches.

Batch-to-batch variability in botanical micropowders can arise from differences in raw material moisture, seasonal harvesting, and drying history. Where the product is intended for direct compression, incoming bulk density should be tracked as an in-process material attribute. A change in bulk density greater than 0.10 g/mL between lots may require adjustment of fill depth or compression force. Sieving through a 250 µm screen before blending is a standard safeguard against agglomerates formed during storage at relative humidity above 60%.

When the Micropowder Is Compounded into Injections and Oral Solutions

For injectable preparations, the API is dissolved or suspended in Water for Injection; if the powder is not sterile, the formulation must be aseptically filtered through a 0.22 µm sterilising-grade membrane or terminally sterilised at 121 °C for 15 min, provided thermal degradation data support the cycle. The endotoxin limit for injectable veterinary products should be aligned with the intended dose and species; a limit of ≤ 0.5 EU/mg is a common starting point but must be justified by body weight and injection volume. Insoluble particulate matter should meet USP <788> for large-volume parenterals and USP <789> for small-volume parenterals. The pH of the final solution should be controlled within a range established by forced degradation studies; botanical APIs often show pH-dependent precipitation below pH 3.0 and above pH 9.0, but specific data for Qizhu Xuanshen is limited.

For oral solutions, the micropowder should be dispersed in a vehicle that maintains homogeneity during the intended in-use period. Sedimentation volume and redispersibility should be tested according to a suitable pharmacopoeial general chapter for oral liquids. Preservative efficacy testing should follow USP <51> or Ph. Eur. 5.1.3 if the solution is multi-dose. If the solution is intended for drinking water administration, solubility in hard water and feed-line compatibility should be confirmed; hardness above 300 ppm as calcium carbonate may reduce stability of some botanical constituents.

In feed premix manufacturing, the micropowder is diluted with a carrier such as calcium carbonate or corncob meal; mixing is commonly performed in a single-shaft paddle mixer with a fill volume of 60–70% and a mixing time of 10–15 min. To reduce segregation, the API is first combined with a 1:1 or 1:5 carrier pre-mix before introduction into the main mixer. Homogeneity is assessed by collecting 10 samples from different mixer zones and calculating relative standard deviation; acceptance is generally RSD ≤ 5.0%. For granulated premixes and oral powders, wet granulation with 2–5% binder solution such as povidone K30 or starch paste is used to increase particle size and reduce dusting. The granules are dried to a final moisture of ≤ 5.0% and sized through a 1.0 mm sieve. Fines below 150 µm should be limited to avoid segregation during sachet filling. Published data for Qizhu Xuanshen in these specific mixer configurations is limited.

Relative to non-micronized botanical powders, the principal difference is particle size distribution and its effect on content uniformity. Crude powders often retain D90 values above 300 µm and exhibit poor flow; the micropowder grade is intended to reduce particle size to a range compatible with direct compression and capsule filling. Compared with spray-dried extracts, the micropowder retains insoluble botanical matrix components, which may affect clarity in solutions and require filtration. Compared with chemically synthesised veterinary APIs, botanical micropowders have multi-component composition, making assay specificity and marker compound selection critical. If the product is used in injectables, residual insoluble fibres and endotoxin burden are higher concerns than for small-molecule pure APIs; therefore, depyrogenation and particulate removal steps are necessary.

Storage of the micropowder should be in airtight high-density polyethylene containers at 20–25 °C and relative humidity below 60%. Pre-drying is required before processing where ambient RH exceeds 60% because hygroscopic uptake can alter flow and compressibility. Incompatibility data for the specific botanical constituents is not publicly available; therefore, combinations with strong oxidising agents, strong acids, and amine-based film coatings should be evaluated by stress stability testing according to ICH Q1A(R2) or the veterinary equivalent before scale-up. Published data for this specific configuration is limited.